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ABSTRACT: Methacholine is frequently used to determine bronchial hyperre-
sponsiveness (BHR) and to generate dose-response curves. These curves are char-
acterized by a threshold (provocative concentration of methacholine producing a
20% fall in forced expiratory volume in one second (PC20) =sensitivity), slope (reac-
tivity) and maximal response (plateau). We investigated the efficacy of 12 weeks
of treatment with 1,000 µg fluticasone propionate in a double-blind, placebo-con-
trolled study in 33 atopic asthmatics.
The outcome measures used were the influence on BHR and the different indices
of the methacholine dose-response (MDR) curve. After 2 weeks run-in, baseline
lung function data were obtained and a MDR curve was measured with doubling
concentrations of the methacholine from 0.03 to 256 mg·mL-1. MDR curves were
repeated after 6 and 12 weeks. A recently developed, sigmoid cumulative Gaussian
distribution function was fitted to the data. Although sensitivity was obtained by
linear interpolation of two successive log2 concentrations, reactivity, plateau and
the effective concentration at 50% of the plateau value (EC50) were obtained as
best fit parameters.
In the fluticasone group, significant changes occurred after 6 weeks with respect
to means of PC20 (an increase of 3.4 doubling doses), plateau value fall in forced
expiratory volume in one second (FEV1) (from 58% at randomization to 41% at
6 weeks) and baseline FEV1 (from 3.46 to 3.75 L) in contrast to the placebo group.
Stabilization occurred after 12 weeks. Changes for reactivity were less marked,
whereas changes in log2 EC50 were not significantly different between the groups.
We conclude that fluticasone is very effective in decreasing the maximal airway
narrowing response and in increasing PC20. However, it is likely that part of this
increase is related to the decrease of the plateau of maximal response.
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Bronchial hyperreactivity (BHR) is a hallmark of asth-
ma. Nonspecific bronchoconstrictor stimuli, such as his-
tamine or methacholine, are widely-used to demonstrate
this BHR and to generate dose-response curves in asth-
matics. These curves are sigmoid in shape, with a distinct
threshold, linear slope in the midpart, and maximum
response [1]. The provocative concentration producing
a fall of 20% in the forced expiratory volume in one
second (PC20) is called the sensitivity, which is lowered
in asthmatics and is associated with a leftward shift of
the dose-response curve [2]. 
The slope in the mid-part is defined as reactivity.
Initially it was felt that slope measurements could pro-
vide relevant information [3] but as yet the clinical rel-
evance of the reactivity is unclear. Asthmatics show an
increased reactivity [1, 4, 5] as compared with normals.
Also, a significant correlation has been found between
reactivity and log2 PC20 in these patients [4, 6]. 
Plateau values reflect maximal airway narrowing. Asth-
matics not only show a leftward shift of the dose-response
curve but also higher or even unmeasurable plateau lev-
els as compared to normals [1].
MORENO et al. [7] postulated that any augmentation
of airway narrowing stimuli ("prejunctional" mecha-
nisms) can result in a leftward shift of the curve, while
any increase in response of the effector organ ("postjunc-
tional" mechanisms) [5, 7] theoretically results in an
increase in the maximal plateau level. In practice, PC20
has been used to diagnose BHR and less attention has
been paid to the overall shape of the dose-response curve
and the plateau value. Previous investigations [1, 4, 5]
have focused on the importance of measuring parame-
ters of the entire log-dose-response curve, i.e. the sen-
sitivity, reactivity and plateau value. Recognition and
distinction of these components of hyperresponsiveness
may have implications for the diagnosis and therapy of
asthma. Although PC20 is generally used as an  index
for the shift of the curve along the concentration axis,
the fit of the sigmoid function also enables calculation
of the effective concentration at half of the plateau
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response (EC50).  This index is commonly used in phar-
macology [8], and is less dependent on the absolute
value of the plateau response.
Anti-inflammatory therapy with inhaled corticosteroids
(ICS) both shifts the dose-response curve to the right,
i.e. decreases sensitivity [9], and reduces the maximum
response [10], presumably by preventing the fixed ele-
ment of airway obstruction caused by inflammation.
A new topically active glucocorticoid, fluticasone pro-
pionate (FP), has been shown to be more clinically
effective than other ICS and to have fewer systemic
side-effects in equi-effective doses at the upper end of
the dose range [11, 12]. The aim of the present study
was to investigate the efficacy of FP, 1,000 µg·day-1,
on BHR and  its in vivo influence on the different char-




Thirty three nonsmoking atopic asthmatics (23 males
and 10 females; median age 26 yrs; range 18–56 yrs)
were selected if they met the following criteria during
the run-in period: PC20 histamine ≤8 mg·mL-1 and ≥9%
reversibility in forced expiratory volume in one second
(FEV1), relative to baseline, following inhalation of 1,000
µg terbutaline. Atopy was defined by at least one posi-
tive skin-prick test to a panel of 16 common aeroaller-
gens in the presence of positive and negative controls.
In the month preceding the run-in period, patients were
allowed to take only inhaled short-acting beta2-agonists,
on an as needed basis. All other medication was stopped.
Patients with a history suggesting respiratory infection
or exacerbation of asthma in the month prior to the study
were excluded.
All subjects gave written informed consent to the
study, which was approved by the local Ethics Committee.
Study design
The study was of a randomized, double-blind, placebo-
controlled design, which is schematically presented in
figure 1. After a run-in period of 2 weeks, there was a
12 week treatment period, and then a follow-up period
of 2 weeks. During the 2 week run-in period, patients
discontinued use of their usual inhaled bronchodilator,
which was replaced with salbutamol 400 µg taken as a
dry powder via the Diskhaler p.r.n. up to a maximum
of eight doses daily. Baseline data were obtained on two
visits, with an interval of 2 weeks. Each baseline visit
consisted of two morning or afternoon sessions. At one
of these sessions, a flow-volume curve was construct-
ed and bronchodilator response was measured; and at
the other session, a provocation test was carried out.
A standardized history regarding respiratory symptoms
was obtained, in addition to flow-volume curve, bron-
chodilator response, and provocation test (see below). At
the second baseline visit, intradermal skin testing was
also performed.
During the run-in period, patients noted the severity
of their asthma symptoms on a daily record card. Symp-
toms related to interference with daily activities were
rated as follows: 0=none; 1=wheezing or shortness of
breath during one episode; 2=wheezing or shortness of
breath during two or more episodes; 3=wheezing or
shortness of breath for most of the day, not interfering
with normal daily activities; 4=wheezing or shortness
of breath for most of the day, normal activities diffi-
cult; 5=unable to carry out normal activities because of
shortness of breath. Symptoms during the night related
to sleep disturbances were rated as follows: 0=none;
1=cough/wheeze/breathlessness causing once or early
wakening; 2=woken two or three times by symptoms;
3=awake most of the night because of cough/wheeze/
breathlessness; 4=awake all night because of asthma
symptoms. Patients also recorded their coughing, spu-
tum production and use of the study medication and
salbutamol inhaler, each day and night. Additionally,
they noted an overall 24 h symptom score concerning dys-
pnoea.
Following the run-in period, the patients were ran-
domized to treatment with either inhaled FP 500 µg or
placebo, both given twice daily as dry powder via the
Diskhaler. Patients continued salbutamol 400 µg p.r.n.
but could take up to eight doses as needed for sympto-
matic relief.
After 6 weeks and 12 weeks of treatment, patients
attended the clinic on two separate days (within three
successive days): on one occasion maximal reversibi-
lity was tested, while on the other a methacholine dose-
response curve (see below) was performed. Two weeks
after the end of the treatment period a follow-up visit
was scheduled.
Lung function testing
Where possible all measurements were made at the
same time of day at each visit, and patients were asked
not to use their bronchodilator or the study medication
for 8 h before attending the clinic.
Inclusion measurements. FEV1 was derived from a maxi-
mal expiratory flow-volume curve, using a pneumota-
























Fig. 1.  –  Design of the study. FP:  fluticasone propionate;  FEV1:
forced expiratory volume in one second.
was tested 20 min after four separate inhalations of 250
µg of terbutaline sulphate from a metered-dose inhaler,
administered through a 750 mL spacer device.
A histamine provocation test was performed by means
of a 2 min tidal breathing method [13] using a nose-
clip.
Study measurements. Maximal reversibility was tested
by administering cumulative doses of terbutaline start-
ing with a single puff of 250 µg, while measuring FEV1
and forced vital capacity (FVC) after 15 min. Measure-
ments were stopped after a maximum of four puffs at
a time were given, or at any time when the difference
between two consecutive measurements was less than
5%.
Methacholine was administered according to a stan-
dardized tidal breathing method [2]. Dose-response
curves were obtained after inhalation of doubling con-
centrations of acetyl-β-methylcholine-bromide (0.03–256
mg·mL-1 in normal saline). 1 mg·mL-1 is equivalent to
0.82 mg·mL-1 of methacholine chloride solution; there-
fore, a fixed conversion constant of 0.29 should be sub-
tracted from the log2 dose values for comparison with
methacholine chloride data. Methacholine and not his-
tamine was chosen as the bronchoconstrictor stimulus
because it produces less systemic side-effects when given
in high doses [14]. Solutions of methacholine were stored
at 4°C and administered at room temperature. The aerosols
were generated by a De Vilbiss 646 nebulizer (output
0.13 ml·min-1) and inhaled by tidal breathing for 2 min.
The response to methacholine was measured as change
in FEV1 expressed as percentage of initial value and
related to log2 dose. A test was interrupted if the FEV1
fell by more than 60%, or if unpleasant side-effects or
dyspnoea compelled the patient to stop.
A recently developed and validated sigmoid cumula-
tive Gaussian distribution (CGD) function was fitted to
the data [4l. Although the sensitivity (log2 PC20) was
obtained by linear interpolation of two successive log2
concentration values [13], the plateau value and the
reactivity (defined as the slope at the 50% point of the
CGD function) and the effective concentration at this
point (EC50) were obtained as best fit parameters. Hence,
reactivity denotes the percentage change from base-
line FEV1 per doubling dose (dd) at the steepest point
of the CGD function. Details of the fit procedure and vali-
dation of the CGD fit are according to AERTS et al. [4].
Statistical analysis
The paired t-test was used to analyse changes in FEV1,
reversibility and indices of bronchial hyperresponsive-
ness with respect to baseline. The unpaired t-test was
used for comparisons between groups. The patient record-
ed diary data were averaged over all days; the Mann-
Whitney test was used for comparison between the
groups. Group means and standard error of the mean
(±SEM) at the various time-points were calculated.
Results
Sixteen patients were randomized into the FP group
and 17 patients into the placebo group. Baseline values
were comparable in both groups on entry to the study
except that a larger mean log2 EC50 methacholine was
found in the FP group (p=0.05). Thirty one of the 33
subjects completed the study (table 1). One patient receiv-
ing placebo and one receiving FP were withdrawn after
experiencing a pulmonary exacerbation. Data of these
two patients have not been included in the analysis. In
one patient, a reliable PC20 methacholine could be
obtained during all methacholine dose-response mea-
surements, but no reliable reactivity or plateau values
were measured. All parameters (PC20 methacholine,
reactivity, EC50 and plateau value) were obtained in 90
out of 93 curves. Although in all cases only the fitted
plateau value was used for the analysis (as mentioned
above), in 61 out of 91 measurements an experimental
plateau could also be obtained. In the remaining curves,
the flattening made it possible to estimate the plateau
value with reasonable accuracy.
Mean values for reactivity (%/dd) and plateau (% fall
in FEV1 from baseline) before, during and after treat-
ment are shown in figure 2. Examples of dose-response
curves to methacholine in the FP and placebo group are
shown before and after 12 weeks of treatment in figure
3. During placebo treatment, mean log2 PC20 metha-
choline hardly changed, from 0.04 (SEM 0.78) at base-
line to 0.34 (0.69) after 6 weeks and to 0.26 (SEM 0.46)
after 12 weeks. During treatment with FP, however,
mean log2 PC20 methacholine increased from 0.31 (SEM
0.59) to 3.73 (SEM 0.69) after 6 weeks and to 3.77 (SEM
0.72) after 12 weeks. After 6 weeks, the mean differ-
ence in change from baseline between the FP and the
placebo group was 3.12 (SEM=0.76) (p<0.0005; 95%
confidence interval (95% CI) 1.57–4.67). After 12
weeks, this was 3.25 (SEM 0.75) (p<0.0005; 95% CI
1.71–4.78).
During placebo treatment, the mean plateau value
hardly changed, as can be seen in figure 2. During treatment
with FP, however, the mean plateau value decreased from
58% (SEM 5%) to 41% (SEM 5%) after 6 weeks and to
36% (SEM 4%) after 12 weeks. After 6 weeks the mean
difference in change from baseline between the FP and
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Table 1.  –  Baseline characteristics of the study patients
Characteristics FP Placebo
Patients  n 16 17
Withdrawals  n 1 1
Sex  M/F 12/4 11/6
Age range  yrs 18–51 18–56
Age  yrs 28 (11) 35 (14)
FEV1 % pred 84 (15) 86 (18)
Reversibility*  % 16   (8) 18 (14)
PC20H  mg·mL-1 0.7 (0.6) 0.9 (0.9)
log2 PC20H  mg·mL-1 -1.1 (1.6) -1.0 (1.7)
log2 EC50M  mg·mL-1 1.3 (1.4) 0.0 (2.0)
Plateau value ‡ % 59 (20) 51 (13)
Reactivity  %/dd 12   (5) 9   (4)
All values are expressed as mean, and SD in parenthesis.  *:
change in FEV1, expressed as percentage baseline, after 1,000
µg terbutaline;  ‡:  plateau value, expressed as percentage fall
in FEV1.  M:  male;  F:  female;  FP:  fluticasone propionate;
FEV1:  forced expiratory volume in one second; % pred:  per-
centage of predicted value;  PC20: provocative concentration
causing a 20% fall in FEV1;  H: histamine;  M:  methacholine;
EC50: effective concentration at half the plateau response;  dd:
doubling dose.
METHACHOLINE DOSE-RESPONSE CURVES 2259
the placebo group was -19.3 (SEM 4.68) (p<0.0005; 95%
CI -28.9 to -9.72). After 12 weeks this difference was
-18.8 (SEM=5.67) (p =0.003; 95% CI -30.4 to -7.15).
In neither of the treatment groups did mean reacti-
vity change substantially (fig. 2). However, there were
significant differences when the results of the treatment
groups were compared. After 6 weeks, the mean dif-
ference in change from baseline between the FP and the
placebo group was -4.05 (SEM=1.60) (p=0.017; 95% CI
-7.32–-0.78). After 12 weeks, this was -3.69 (SEM=1.87)
(p=0.058; 95% CI -7.52–0.13).
Log2 EC50 changes with respect to baseline were not
significantly different between the groups. The mean
values were 0.0 (SEM 0.5), 0.8 (SEM 0.5), 0.2 (SEM 0.4)
mg·mL-1 for the placebo group and 1.3 (SEM 0.4), 2.9
(SEM 0.4), 2.4 (SEM 0.3) mg·mL-1 for the FP group, at
baseline, 6 and 12 weeks, respectively. No significant
correlation was found between Log2 EC50 and plateau
estimates.
Baseline values for FEV1 as absolute values hardly
changed during placebo treatment. FEV1 decreased
from 3.27 (SEM 0.24) L at baseline to 3.02 (SEM 0.23) L
after 6 weeks and to 3.07 (SEM 0.24) L after 12 weeks.
In the FP group FEV1 increased significantly from 3.46
(SEM 0.25) L at baseline to 3.75 (SEM 0.24) L after 6
weeks and to 3.73 (SEM 0.22) L after 12 weeks. After 6
weeks, the mean difference in change from baseline
between the FP and the placebo group was 0.54 (SEM 0.17)
(p=0.003; 95% CI 0.19–0.88) after 6 weeks, and 0.47
(SEM 0.16) (p=0.007; 95% CI 0.14–0.81) after 12 weeks.
Because of the skewed distribution of the data, max-
imal reversibility was analysed after log transformation.
After 6 weeks, maximum reversibility in the FP group
was 68% lower in comparison to the placebo group
(95% CI 37–84%; p=0.002). After 12 weeks this was
54% (95% CI 11–76%; p= 0.022).
Compared with placebo, FP significantly improved indi-














































































































Fig. 2.  –  a) Plateau value (percentage fall in FEV1 from baseline;  and b)  reactivity (%/dd) before, during and after treatment with placebo
(—❏—) and fluticasone propionate (—■—).  Values are presented as mean±SEM.  FEV1:  forced expiratory volume in one second;  dd:  dou-
bling dose.
Fig. 3.  –  Examples of dose-response curves to methacholine before (❍) and 12 weeks after treatment (●) with: a)  placebo; and b)  fluticas-
one propionate.  FEV1:  forced expiratory volume in one second.
log2 dose  · L-1 2 ose  mg·mL-1
at end-point (p=0.01), whereas individual daytime symp-
tom score (interfering with normal daily activities) almost
reached significance (p=0.06). The overall 24 h symp-
tom score also significantly improved in the FP treated
group compared with placebo (p=0.01).
Discussion
The aim of the present study was to investigate the
efficacy of a new inhaled corticosteroid, fluticasone pro-
pionate (FP), on BHR and its in vivo influence on the
different characteristics of the methacholine dose-res-
ponse curve in atopic asthmatics.
The results of the study show that FP is very effec-
tive in decreasing the maximal degree of airway nar-
rowing after 6 weeks of treatment, and that this effect
is sustained after 12 weeks. An improvement in FEV1
was accompanied by an increase in PC20 methacholine
and a decrease in plateau value in the FP group but not
in the placebo group. Although log2 EC50 increased more
in the FP group than in the placebo group the differ-
ence between these changes was not significant. Reac-
tivity improved only slightly in the first 6 weeks of
treatment with FP.
For the interpretation of the entire dose-response curve
a recently developed and validated sigmoid function
(cumulative Gaussian distribution) was fitted to the data
[4]. Although the sensitivity (log2 PC20) was obtained
by linear interpolation of two successive log2 concen-
tration values, the reactivity defined as the slope at the
50% point of the CGD function (%/dd), EC50 and the
plateau value were obtained as additional fit para-
meters. The model fit was used for two reasons: firstly,
because it enabled smoothing of the curve, thereby min-
imizing fluctuations due to variation in patient co-oper-
ation or other causes; and secondly, because it facilitated
extrapolation of the whole curve, where it was impos-
sible to obtain direct estimates of plateau values, because
of, for example, severe dyspnoea of the patient or feel-
ings of general discomfort, which occasionally forced
an interruption of the measurements [4]. In the present
investigation, however, prolonged administration of
methacholine was possible beyond the fitted plateau
value in 67% of the cases, which further contributed
to the reliability of reactivity and plateau estimates.
In contrast to other studies [9, 15–17] the improve-
ment in PC20 methacholine in the present study is high
(approximately 3.5 doubling doses after 6 and 12 weeks).
This may be due to differences between the patients
studied (atopic asthmatics [15] versus nonatopic asth-
matics [9]), or to a difference in study medication pre-
scribed [9, 15–17], or dosage used [9, 15–17]. Also, the
difference in provocative concentration used [18] makes
comparison difficult, although we know that in asthma
PC20 is similar for histamine and methacholine [18, 19].
The greater increase in PC20 methacholine found in
the present study may be due to the relatively high dose
and/or high efficacy of FP prescribed. The normal daily
dose of inhaled steroids in mild-to-moderate asthma
varies somewhere between 800–1,200 µg. One recent
investigation demonstrated that 200 µg FP was as effec-
tive as 400 µg beclomethasone dipropionate with respect
to peak expiratory flow (PEF) rate, symptom scores,
percentage of symptom-free days and nights, use of rescue
β2-agonist medication and clinical lung function [20].
This was also shown by others [11, 21]. Taking these
results into account, the daily dose of 1,000 µg FP used
in the present study may be considered to be relatively
high; this could, in part, explain the large improvement
in PC20 methacholine. True comparisons with the above-
mentioned studies remain difficult, however, because
none of them investigated the differences in effect on
PC20 between FP and the other inhaled steroids.
Another reason for careful interpretation of the study
results is the interaction between changes in plateau esti-
mates (a postjunctional index [5]) and PC20 (sensitivity,
presumed to be a prejunctional index). EC50, as a phar-
macologically well-based index for the horizontal shift
of sigmoid curves, independent of the plateau value, was
found to change similarly in both groups. This means
that part of the PC20 changes may be due to changes in
plateau values, which in turn makes comparisons between
different studies difficult.
It is possible that, since PC20 methacholine was not
measured sooner than after 6 weeks of treatment, the
effect measured may have occurred earlier than this time.
After 12 weeks of treatment, no further improvement
was found. This is in keeping with the findings of others
[16, 22]. KERSTJENS et al. [22] demonstrated, in patients
with obstructive lung diseases (chronic obstructive pul-
monary disease and asthma), that the largest improve-
ment in PC20 histamine occurred after 6 months of
treatment. Continuation of the therapy in their study
resulted in only a slight, but not significant, further in-
crease. HAAHTELA et al. [17] also showed, in patients with
newly detected asthma, that the marked decrease in
bronchial responsiveness was already apparent after 6
weeks of treatment; although this decrease continued
over the 2 yrs of the study, the trend over time was not
significant.
FP also influenced the plateau value of the metha-
choline dose-response curve, whereas no change was
observed during placebo treatment. FP induced a sig-
nificant decrease in percentage fall in FEV1 after 6
weeks. A further, although not significant, decrease was
found after 12 weeks. This finding may be of clinical
importance. A maximal response that is increased to a
severe or even unmeasurable degree of airway narrow-
ing is potentially dangerous. The major reason why asth-
matics get into trouble is not primarily the increased
sensitivity of their airways to bronchoconstrictor stim-
uli, but the excessive degree of airway narrowing [23,
24]. Successful treatment of their asthma, therefore,
should be directed towards preventing or at least dimin-
ishing this excessive response. Like other steroids, FP
may result in diminished airway wall thickness by its
effect on inflammatory mediators, decreasing mucosal
swelling or plasma exudation [5]. Since we have shown
FP to be very effective in diminishing the plateau value,
it may, in our opinion, be considered a useful addition
to the already existing arsenal of ICS.
Reactivity has been defined in some studies as the
slope of the line fitted to the data upward from the
threshold (PC20) [6, 25, 26]. In our opinion, such an
approach becomes inaccurate because of the curvilinear
shape reached at higher doses. Therefore, reactivity is
better defined as the steepest slope of the log dose-
response curve (50% point of the CGD function), thus
S.E. OVERBEEK ET AL. 2260
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enabling comparison of reactivity estimates between
different investigations. In the present study, FP also
influenced reactivity. Although small changes were found
after placebo as well as after FP treatment, only the
change caused by FP from baseline to 6 weeks reached
significance in comparison with placebo. After 6 weeks,
a stabilization of reactivity seemed to occur. The change
in reactivity during the first 6 weeks of FP treatment
may be because, in the presence of an increasing stim-
ulus, airway obstruction develops less progressively after
treatment with FP than without treatment. Although reac-
tivity is certainly coupled to pharmacodynamic proper-
ties, its interpretation is as yet unclear [6, 26, 27]. Further
investigations will be needed in this respect to fully
understand the clinical implications of the present find-
ings.
Like other ICS [16, 22l, treatment with FP increased
FEV1 and decreased maximal reversibility, as can be
expected when baseline values increase. Improvements
in asthma symptom scores were not as consistent as the
changes in lung function, with only the night-time and
overall 24 h scores being significant. The present results
confirmed those found by AYRES et al. [12]. An expla-
nation may be that some symptom questions are more
sensitive measures for the disease than others. The
finding that lung function parameters had already signif-
icantly improved after 6 weeks of treatment with FP,
whereas symptom scores only showed significant changes
after 12 weeks of treatment, was interesting. This dis-
crepancy may be explained by the fact that in a short-
term study lung function changes precede symptom
improvements.
In conclusion, fluticasone propionate proved to be
very effective in decreasing the maximal response of
airway narrowing in atopic asthmatic patients. The
changes in provocative concentration of methacholine
causing a 20% fall in forced expiratory volume in one
second could suggest that an effect is exerted on sen-
sitivity. However, the lack of significance in changes in
the effective concentration at half of the plateau response
makes this doubtful. Further studies are, therefore, war-
ranted on this aspect.
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